ADHD Trial, Recruiting NCT04627415 Sponsor: Lehigh University Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT04627415
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children aged 3 to 5 years and 11 months who have clinically significant symptoms of ADHD.
  • Children who have been assessed by a clinician and found to meet the diagnostic guidelines (DSM-5) for one of the three types of ADHD, based on a clinical interview along with behaviour ratings completed by a parent and a teacher — including reports of significant difficulties at home and at school (specifically, scoring above the 90th percentile on one or more relevant sections of the Conners Early Childhood Rating Scale).

Who may not be able to join:

  • Children who have a diagnosis of autism spectrum disorder (ASD), pervasive developmental disorder, intellectual disability, neurological damage, or significant physical or movement-related impairments.
  • Children who are not enrolled in a preschool or daycare setting for at least 2 days per week — unless they are unable to attend due to behavioural difficulties or a lack of available services for an unrelated condition — as attendance in two settings is needed to confirm symptoms are present across different environments.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: George J DuPaul, Ph.D., Lehigh University

Phone: 6107583252

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lehigh University
Registry
ClinicalTrials.gov
Start date
1 September 2020
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Post-Treatment Effects (Parent): Intervention Strategies; Post-Treatment Effects (Parent): Behavior; Post-Treatment Effects (Parent): Acceptability; Post-Treatment Effects (Parent): Stress; Post-Treatment Effects (Parent): Optimism; Post-Treatment Effects (Child): Academics; Post-Treatment Effects (Child): Behavior; Post-Treatment Effects (Child): Behavior Observations; Post-Treatment Effects (Child): Self Regulation; Post-Treatment Effects (Child): Bedtime Behaviors; Post-Treatment Effects (Child): Social Behaviors; Post-Treatment Effects (Child): Social Behaviors; Maintenance (Child): Behavi...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov